Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.56 |
| ▸ | SELL | P14151 | 1/20 | 0.48 |
| ▸ | SELP | P16109 | 1/20 | 0.48 |
| ▸ | SELE | P16581 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.46 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19701362 | 1.00 | SIGMAR1 (0.56) | SIGMAR1SELLSELPSELELMNA | |
| SCHEMBL30590284 | 0.90 | LMNA (0.52) | SIGMAR1SELLSELPSELELMNA | |
| SCHEMBL23575873 | 0.85 | SMYD3 (0.61) | SIGMAR1SELLSELPSELESMYD3 | |
| SCHEMBL19710224 | 0.85 | SMYD3 (0.61) | SIGMAR1SELLSELPSELESMYD3 | |
| SCHEMBL21489943 | 0.84 | LMNA (0.59) | SIGMAR1LMNAEPHX2CCR3 | |
| SCHEMBL19701309 | 0.84 | LMNA (0.59) | SIGMAR1LMNAEPHX2CCR3 | |
| SCHEMBL30590257 | 0.82 | LMNA (0.47) | SIGMAR1SELLSELPSELELMNA | |
| Hydrochloric Acid SCHEMBL30590247 | 0.81 | LMNA (0.46) | SIGMAR1SELLSELPSELELMNA | |
| Hydrochloric Acid SCHEMBL30590301 | 0.81 | LMNA (0.46) | SIGMAR1SELLSELPSELELMNA | |
| Hydrochloric Acid SCHEMBL30590262 | 0.81 | LMNA (0.46) | SIGMAR1SELLSELPSELELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | claimed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | SIGMAR1 1193/4885SELL 4438/4885SELP 3812/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | SIGMAR1 546/4885SELL 4564/4885SELP 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.